XML 14 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Balance Sheets - USD ($)
Jun. 30, 2019
Sep. 30, 2018
CURRENT ASSETS    
Cash and cash equivalents $ 188,331,747 $ 30,133,213
Restricted cash 1,000,000 0
Accounts receivable 2,044,111 327,375
Prepaid expenses 3,103,476 1,267,717
Other current assets 1,492,175 640,117
Short term investments 48,567,215 46,400,176
TOTAL CURRENT ASSETS 244,538,724 78,768,598
Property and equipment, net 17,074,613 13,935,425
Intangible assets, net 17,488,688 18,764,010
Long term investments 57,555,499  
Other assets 170,921 141,918
TOTAL ASSETS 336,828,445 111,609,951
CURRENT LIABILITIES    
Accounts payable 4,630,244 2,806,098
Accrued expenses 5,173,146 5,043,087
Accrued payroll and benefits 1,427,855 3,937,605
Deferred rent 173,952 307,334
Deferred revenue 75,681,868 600
Note payable   223,820
Other current liabilities   46,407
TOTAL CURRENT LIABILITIES 87,087,065 12,364,951
LONG-TERM LIABILITIES    
Deferred rent, net of current portion 1,812,346 1,702,801
Deferred revenue, net of current portion 22,258,994  
Note payable, net of current portion   2,101,198
Other non-current liabilities   200,000
TOTAL LONG-TERM LIABILITIES 24,071,340 4,003,999
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders' equity:    
Common stock, $0.001 par value; 145,000,000 shares authorized; 95,207,637 and 88,505,302 shares issued and outstanding as of June 30, 2019 and September 30, 2018, respectively 187,577 180,875
Additional paid-in capital 657,136,601 582,902,694
Accumulated other comprehensive income (loss) (103,078) (21,564)
Accumulated deficit (430,995,872) (487,265,816)
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity 226,225,228 95,796,189
Noncontrolling interest (555,188) (555,188)
TOTAL STOCKHOLDERS’ EQUITY 225,670,040 95,241,001
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 336,828,445 $ 111,609,951